CytoDyn Inc. (CYDY)
USD 0.23
(-1.61%)
USD 0.23
(-1.61%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 11.13 Million USD | -1.38% |
| 2023 | 11.29 Million USD | -61.31% |
| 2022 | 29.18 Million USD | -77.9% |
| 2021 | 132.08 Million USD | 161.47% |
| 2020 | 50.51 Million USD | 141.99% |
| 2019 | 20.87 Million USD | 326.09% |
| 2018 | 4.89 Million USD | -39.18% |
| 2017 | 8.05 Million USD | -41.57% |
| 2016 | 13.78 Million USD | 194.62% |
| 2015 | 4.67 Million USD | -44.47% |
| 2014 | 8.42 Million USD | 102.69% |
| 2013 | 4.15 Million USD | 288.27% |
| 2012 | 1.07 Million USD | -46.31% |
| 2011 | 1.99 Million USD | 166.79% |
| 2010 | 747.64 Thousand USD | 145.34% |
| 2009 | 304.74 Thousand USD | 72.93% |
| 2008 | 176.22 Thousand USD | 54.23% |
| 2007 | 114.25 Thousand USD | -73.58% |
| 2006 | 432.43 Thousand USD | 812.45% |
| 2005 | 47.39 Thousand USD | -77.09% |
| 2004 | 206.89 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 FY | 11.13 Million USD | -1.38% |
| 2024 Q1 | 12.41 Million USD | 9.91% |
| 2024 Q2 | 9.24 Million USD | -25.55% |
| 2024 Q3 | 10.27 Million USD | 11.15% |
| 2024 Q4 | 11.13 Million USD | 8.43% |
| 2023 Q4 | 11.29 Million USD | -22.88% |
| 2023 Q3 | 14.64 Million USD | 106.98% |
| 2023 Q1 | 28.39 Million USD | -2.71% |
| 2023 FY | 11.29 Million USD | -61.31% |
| 2023 Q2 | 7.07 Million USD | -75.09% |
| 2022 Q2 | 103.69 Million USD | -1.21% |
| 2022 FY | 29.18 Million USD | -77.9% |
| 2022 Q1 | 104.97 Million USD | -20.53% |
| 2022 Q4 | 29.18 Million USD | -68.98% |
| 2022 Q3 | 94.07 Million USD | -9.28% |
| 2021 FY | 132.08 Million USD | 161.47% |
| 2021 Q3 | 113.65 Million USD | -20.94% |
| 2021 Q2 | 143.76 Million USD | 53.98% |
| 2021 Q1 | 93.36 Million USD | 84.82% |
| 2021 Q4 | 132.08 Million USD | 16.21% |
| 2020 Q2 | 17.91 Million USD | -2.55% |
| 2020 Q4 | 50.51 Million USD | 30.13% |
| 2020 FY | 50.51 Million USD | 141.99% |
| 2020 Q1 | 18.38 Million USD | -11.92% |
| 2020 Q3 | 38.81 Million USD | 116.65% |
| 2019 Q3 | 20.42 Million USD | 0.18% |
| 2019 FY | 20.87 Million USD | 326.09% |
| 2019 Q4 | 20.87 Million USD | 2.19% |
| 2019 Q1 | 9.03 Million USD | 84.35% |
| 2019 Q2 | 20.39 Million USD | 125.78% |
| 2018 Q2 | 6.49 Million USD | 5.93% |
| 2018 FY | 4.89 Million USD | -39.18% |
| 2018 Q4 | 4.89 Million USD | -40.87% |
| 2018 Q3 | 8.28 Million USD | 27.63% |
| 2018 Q1 | 6.12 Million USD | -23.93% |
| 2017 FY | 8.05 Million USD | -41.57% |
| 2017 Q4 | 8.05 Million USD | -45.41% |
| 2017 Q3 | 14.75 Million USD | -5.84% |
| 2017 Q2 | 15.67 Million USD | 68.66% |
| 2017 Q1 | 9.29 Million USD | -32.59% |
| 2016 FY | 13.78 Million USD | 194.62% |
| 2016 Q4 | 13.78 Million USD | -5.48% |
| 2016 Q3 | 14.58 Million USD | 122.3% |
| 2016 Q2 | 6.56 Million USD | 6.89% |
| 2016 Q1 | 6.13 Million USD | 31.19% |
| 2015 Q4 | 4.67 Million USD | 0.1% |
| 2015 FY | 4.67 Million USD | -44.47% |
| 2015 Q1 | 5.58 Million USD | -33.72% |
| 2015 Q2 | 5.66 Million USD | 1.39% |
| 2015 Q3 | 4.67 Million USD | -17.46% |
| 2014 FY | 8.42 Million USD | 102.69% |
| 2014 Q2 | 13.64 Million USD | 206.83% |
| 2014 Q4 | 8.42 Million USD | -23.5% |
| 2014 Q1 | 4.44 Million USD | 6.95% |
| 2014 Q3 | 11.01 Million USD | -19.25% |
| 2013 Q1 | 842.36 Thousand USD | -21.34% |
| 2013 FY | 4.15 Million USD | 288.27% |
| 2013 Q4 | 4.15 Million USD | -7.19% |
| 2013 Q3 | 4.47 Million USD | -19.48% |
| 2013 Q2 | 5.56 Million USD | 560.42% |
| 2012 FY | 1.07 Million USD | -46.31% |
| 2012 Q2 | 981.07 Thousand USD | -33.28% |
| 2012 Q3 | 2.55 Million USD | 160.49% |
| 2012 Q4 | 1.07 Million USD | -58.1% |
| 2012 Q1 | 1.47 Million USD | -26.28% |
| 2011 Q3 | 3.37 Million USD | 2024.85% |
| 2011 Q4 | 1.99 Million USD | -40.9% |
| 2011 Q1 | 465.06 Thousand USD | -37.8% |
| 2011 FY | 1.99 Million USD | 166.79% |
| 2011 Q2 | 158.84 Thousand USD | -65.85% |
| 2010 Q1 | 141.6 Thousand USD | -53.53% |
| 2010 Q4 | 747.64 Thousand USD | -34.71% |
| 2010 FY | 747.64 Thousand USD | 145.34% |
| 2010 Q2 | 179.5 Thousand USD | 26.77% |
| 2010 Q3 | 1.14 Million USD | 537.94% |
| 2009 Q2 | 103.79 Thousand USD | 14.01% |
| 2009 Q1 | 91.04 Thousand USD | -48.33% |
| 2009 FY | 304.74 Thousand USD | 72.93% |
| 2009 Q4 | 304.74 Thousand USD | 384.56% |
| 2009 Q3 | 62.89 Thousand USD | -39.41% |
| 2008 Q1 | 94.66 Thousand USD | -17.15% |
| 2008 Q4 | 176.22 Thousand USD | 191.1% |
| 2008 Q3 | 60.53 Thousand USD | -33.83% |
| 2008 Q2 | 91.48 Thousand USD | -3.36% |
| 2008 FY | 176.22 Thousand USD | 54.23% |
| 2007 Q1 | 846.13 Thousand USD | 95.67% |
| 2007 Q3 | 204.9 Thousand USD | -34.31% |
| 2007 Q4 | 114.25 Thousand USD | -44.24% |
| 2007 FY | 114.25 Thousand USD | -73.58% |
| 2007 Q2 | 311.92 Thousand USD | -63.13% |
| 2006 Q4 | 432.43 Thousand USD | 33.05% |
| 2006 Q1 | 130.5 Thousand USD | 175.37% |
| 2006 Q2 | 55.89 Thousand USD | -57.17% |
| 2006 Q3 | 325.02 Thousand USD | 481.49% |
| 2006 FY | 432.43 Thousand USD | 812.45% |
| 2005 Q2 | 20.87 Thousand USD | -77.5% |
| 2005 FY | 47.39 Thousand USD | -77.09% |
| 2005 Q3 | 90.53 Thousand USD | 333.61% |
| 2005 Q1 | 92.79 Thousand USD | -55.15% |
| 2005 Q4 | 47.39 Thousand USD | -47.65% |
| 2004 Q2 | 12.67 Thousand USD | 26304.17% |
| 2004 Q3 | 176.75 Thousand USD | 1294.65% |
| 2004 FY | 206.89 Thousand USD | 0.0% |
| 2004 Q1 | 48.00 USD | 0.0% |
| 2004 Q4 | 206.89 Thousand USD | 17.05% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -481977.922% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -468.689% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -5.514% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1916.953% |
| Rebus Holdings, Inc. | 5000.00 USD | -222620.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 91.448% |
| Qrons Inc. | 420.00 USD | -2651328.571% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1345.025% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 60.149% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -2217.311% |
| Skye Bioscience, Inc. | 11.94 Million USD | 6.737% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 71.334% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -54.243% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -14484.698% |
| SQZ Biotechnologies Company | 107.18 Million USD | 89.611% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -677.636% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -15288.655% |
| Mesoblast Limited | 667.9 Million USD | 98.333% |
| Marizyme, Inc. | 22.01 Million USD | 49.416% |
| Genus plc | 1.02 Billion USD | 98.918% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -719.816% |
| Pharming Group N.V. | 462.85 Million USD | 97.594% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -236.129% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -2131.489% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1676.077% |
| ContraFect Corporation | 20.67 Million USD | 46.148% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -2752.707% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -2813.833% |
| IMV Inc. | 31.33 Million USD | 64.46% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -168.595% |
| MultiCell Technologies, Inc. | 126.22 USD | -8822590.54% |
| ONE Bio Corp. | 70.08 Million USD | 84.111% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1085.073% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 91.335% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -2479.485% |
| Q BioMed Inc. | 3.51 Million USD | -216.767% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 68.345% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -4162.143% |
| Biomind Labs Inc. | 73.81 Thousand USD | -14985.547% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 97.505% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -668.613% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 62.898% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -305.486% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1519.815% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -327.782% |
| GB Sciences, Inc. | 103.44 Thousand USD | -10665.453% |
| Alpha Cognition Inc. | 2.45 Million USD | -354.128% |
| HST Global, Inc. | 1526.00 USD | -729650.983% |
| CSL Limited | 38.02 Billion USD | 99.971% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1027.163% |
| Halberd Corporation | 10.13 Thousand USD | -109820.047% |
| Enzolytics Inc. | 361.7 Million USD | 96.921% |
| Agentix Corp. | 261.39 Thousand USD | -4160.268% |
| Resverlogix Corp. | 8.11 Million USD | -37.227% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -493.009% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.755% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 76.655% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1640.936% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -48782.841% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -24.436% |
| AVAX Technologies, Inc. | 7.37 Million USD | -50.952% |
| Zenith Capital Corp. | 7410.00 USD | -150183.401% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.671% |
| Ember Therapeutics, Inc. | 184.00 USD | -6052073.913% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -3360.47% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -4160.725% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1100.05% |
| Kadimastem Ltd | 2.3 Million USD | -383.317% |
| Helix BioMedix, Inc. | 3.02 Million USD | -268.122% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 78.869% |
| BioStem Technologies, Inc. | 14.56 Million USD | 23.518% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -19404.676% |
| LadRx Corporation | 2.3 Million USD | -382.52% |
| Cell Source, Inc. | 195.17 Thousand USD | -5605.766% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -3049.17% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -3049.17% |
| NovAccess Global Inc. | 62.24 Thousand USD | -17789.731% |
| Affymax, Inc. | 7.44 Million USD | -49.617% |
| Itoco Inc. | 1.4 Million USD | -695.388% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -11541.594% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -10405.66% |
| Mobile Lads Corp. | 52.00 USD | -21415284.615% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -7688.938% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -62181.879% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -2788.933% |
| SYBLEU INC | 330.46 Thousand USD | -3269.767% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -2619.932% |
| International Stem Cell Corporation | 5.39 Million USD | -106.605% |
| Bioxytran, Inc. | 137.63 Thousand USD | -7990.789% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 25.769% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 32.831% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -13996.203% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1187.88% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -48.144% |
| Neutra Corp. | 2851.00 USD | -390499.79% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 65.636% |
| PureTech Health plc | 693.97 Million USD | 98.395% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -37.974% |
| IXICO plc | 15.84 Million USD | 29.714% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -34.46% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 89.222% |
| CSL Limited | 38.02 Billion USD | 99.971% |
| Cellectis S.A. | 333.99 Million USD | 96.666% |